My laboratory is primarily focused on determining the role of Notch signaling in T-cell acute lymphoblastic leukemia (T-ALL) and other cancers. Notch receptors participate in a signaling pathway that controls normal differentiation and many other fundamental cellular processes, and dysregulated Notch signaling has been implicated in virtually all the pathological hallmarks of cancer, as well as in clinically important phenomena such as drug resistance.

We are studying resistance to drugs that inhibit the Notch signaling pathway using cutting edge tools like single cell “omics” and genome-wide CRISPR screens. I have received many awards for my contributions to cancer research and am a Professor of Pathology at Brigham and Women’s Hospital and Harvard Medical School, chief of Hematopathology at Brigham and Women’s Hospital and co-leader of the Cancer Research Center of the Brigham Biomedical Research Institute. I received my M.D. and a Ph.D. from the University of Michigan at Ann Arbor.